<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042273</url>
  </required_header>
  <id_info>
    <org_study_id>PAC-001</org_study_id>
    <nct_id>NCT03042273</nct_id>
  </id_info>
  <brief_title>High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of High Strength Cranberry (Pacran®) in Women With Recurrent Urinary Tract Infections (Cystitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swisse Wellness Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commonwealth Scientific and Industrial Research Organisation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swisse Wellness Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 2, multicenter, placebo-controlled, double-blind, parallel-arm
      study to evaluate the efficacy and safety of High Strength Cranberry (500mg Pacran®) in
      preventing UTI (cystitis) in women with a history of recurrent UTI (rUTI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of UTI</measure>
    <time_frame>6 months</time_frame>
    <description>cultured confirmed UTIs at a level of &gt;108cfu/L (105cfu/mL)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>High Strength Cranberry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule of Matching Placebo orally daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Strength Cranberry</intervention_name>
    <description>Softgel capsule</description>
    <arm_group_label>High Strength Cranberry</arm_group_label>
    <other_name>25,000mg Vaccinium macrocarpon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Soy oil to match High Strength Cranberry Softgel Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (for High Strength Cranberry)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females aged 18-65 years, inclusive

          2. A history of recurrent urinary tract infection defined as ≥3 UTIs in the last year OR
             at least 2 UTIs occurring in the last 6 months. Each infection requires confirmation
             by a health professional

          3. Willing to answer questionnaires and comply with the study requirements

          4. Ability to swallow capsules

          5. Provided Written Informed Consent

          6. BMI &gt;17.5kg m2 and &lt;35kg m2

        Exclusion Criteria:

          1. Microbial growth on urine culture of ≥107 cfu/L (104cfu/mL) within 7 days of Day 1

          2. A history of &gt;5 UTIs in the last 6 months (confirmed by self-report or health
             professional)

          3. Use of antibiotics or antibiotics for prophylaxis within 28 days of Day 1

          4. Use of any antibacterial products, that in the opinion of the Medical Investigator may
             interfere with the study outcomes, within 28 days of Day 1

          5. Regular use of Vaccinium containing products (e.g. all forms of blueberries,
             cranberries, bilberry, lingonberry , etc i.e fruit, dried fruit, pills, juices or
             supplements) within 28 days of Day 1 at the discretion of the Medical Investigator

          6. Presence of an intermittent or indwelling urinary catheter

          7. Anatomical abnormalities of the urinary tract

          8. History of or known clinically significant renal or urological disease(self-reported)

          9. Positive urine dipstick pregnancy test at screening onDay 1, currently pregnant and/or
             breastfeeding

         10. Women of Childbearing potential not willing to use adequate and effective methods of
             contraception throughout the study

         11. Women of child bearing potential that have not been using effective methods of
             contraception for 14 days prior to Day 1

         12. History of or known clinically significant cardiac disease

         13. History of or known clinically significant liver disease

         14. History of or known clinically significant gastrointestinal disease

         15. History of or known metabolic disorder or diabetes

         16. History or presence of alcohol or illicit drug abuse,any surgical history, clinical
             condition or organ dysfunction that in the opinion of the Medical Investigator may
             affect the participant's ability to participate in the study or the study results

         17. Currently hospitalised or any planned hospitalisations within 1 month following the
             last dose of study product

         18. Immunocompromised participants or participants receiving immunosuppressive medication

         19. History of an adverse reaction or known hypersensitivity or suspected allergy to the
             investigational product ingredients

         20. Currently taking warfarin or has received Warfarin within 28 days of Day 1

         21. Received an investigational drug within 28 days of Day 1
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females with a history of recurrent UTIs</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Welma Stonehouse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSIRO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holdsworth House Medical Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Griffith University Clinical Trial Unit (Griffith Health)</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4222</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSIRO Nutrition and Health Research Clinic</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre (MAPrc)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

